A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
Completed · Phase 3 · NCT03730662
Conditions: Type 2 Diabetes Mellitus
At a glance
- Research payments reported, 2025
- $3
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 2,002
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Tirzepatide (drug), Insulin Glargine (drug)
- Dates
- Started 2018-11-20; completion 2021-04-22
- Results posted
- Yes
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk. The study will last about 108 weeks and may include up to 30 visits.
From ClinicalTrials.gov, last updated 2022-02-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $3 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.